Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 6 | 2025 | 351 | 2.240 |
Why?
|
| Neoplasms | 8 | 2025 | 3340 | 1.010 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 2457 | 0.760 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 826 | 0.740 |
Why?
|
| Head and Neck Neoplasms | 3 | 2025 | 1088 | 0.670 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 17 | 0.660 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 140 | 0.660 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2025 | 384 | 0.650 |
Why?
|
| Kidney Neoplasms | 1 | 2025 | 556 | 0.600 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 585 | 0.560 |
Why?
|
| MicroRNAs | 1 | 2023 | 604 | 0.550 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 1173 | 0.490 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 638 | 0.450 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 1103 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 1105 | 0.410 |
Why?
|
| Neoplasm Metastasis | 4 | 2025 | 1089 | 0.370 |
Why?
|
| Papillomavirus Infections | 2 | 2025 | 311 | 0.340 |
Why?
|
| Humans | 24 | 2025 | 97883 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2025 | 1536 | 0.280 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 3272 | 0.270 |
Why?
|
| Prospective Studies | 5 | 2025 | 4798 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 2658 | 0.220 |
Why?
|
| Motor Neuron Disease | 2 | 2014 | 20 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 2 | 2025 | 478 | 0.210 |
Why?
|
| DNA, Viral | 1 | 2025 | 238 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2025 | 82 | 0.200 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2023 | 31 | 0.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 68 | 0.200 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2025 | 152 | 0.190 |
Why?
|
| Rectal Neoplasms | 1 | 2024 | 138 | 0.190 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2023 | 110 | 0.190 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 23 | 0.180 |
Why?
|
| Chemoradiotherapy | 1 | 2025 | 337 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2025 | 968 | 0.180 |
Why?
|
| Female | 11 | 2025 | 51464 | 0.180 |
Why?
|
| Fluorouracil | 1 | 2023 | 541 | 0.180 |
Why?
|
| Middle Aged | 8 | 2025 | 29353 | 0.170 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 618 | 0.170 |
Why?
|
| Pneumonia | 1 | 2022 | 195 | 0.160 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 2080 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 473 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 7386 | 0.150 |
Why?
|
| Male | 10 | 2025 | 46992 | 0.150 |
Why?
|
| Motivation | 1 | 2022 | 343 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2023 | 10947 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 446 | 0.140 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 4023 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 532 | 0.120 |
Why?
|
| Aged | 5 | 2025 | 21702 | 0.120 |
Why?
|
| Quality of Life | 1 | 2025 | 1891 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 550 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1764 | 0.120 |
Why?
|
| Mass Screening | 1 | 2021 | 745 | 0.120 |
Why?
|
| Cerebellum | 2 | 2014 | 253 | 0.120 |
Why?
|
| Neural Pathways | 2 | 2014 | 332 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1750 | 0.120 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2014 | 23 | 0.110 |
Why?
|
| Adult | 5 | 2025 | 29453 | 0.110 |
Why?
|
| Brain Mapping | 2 | 2014 | 570 | 0.110 |
Why?
|
| Corpus Callosum | 1 | 2014 | 58 | 0.110 |
Why?
|
| Papillomaviridae | 2 | 2025 | 184 | 0.100 |
Why?
|
| Mood Disorders | 1 | 2014 | 86 | 0.100 |
Why?
|
| Cerebral Cortex | 2 | 2014 | 571 | 0.100 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2014 | 154 | 0.100 |
Why?
|
| Nerve Net | 1 | 2014 | 401 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2022 | 821 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 3606 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 3021 | 0.050 |
Why?
|
| Carboplatin | 1 | 2025 | 331 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2025 | 483 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2024 | 330 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 153 | 0.050 |
Why?
|
| Methylation | 1 | 2023 | 294 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 68 | 0.050 |
Why?
|
| Disease Management | 1 | 2024 | 377 | 0.040 |
Why?
|
| Immune System | 1 | 2022 | 106 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1284 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 156 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 595 | 0.040 |
Why?
|
| Pons | 1 | 2014 | 25 | 0.030 |
Why?
|
| Pyramidal Tracts | 1 | 2014 | 16 | 0.030 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 33 | 0.030 |
Why?
|
| Anisotropy | 1 | 2014 | 61 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2014 | 78 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2666 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 9682 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 642 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1384 | 0.020 |
Why?
|
| United States | 1 | 2021 | 8184 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 4000 | 0.020 |
Why?
|
| Child | 1 | 2014 | 7680 | 0.010 |
Why?
|